|
|
|
Insider
Information: |
Powchik Peter |
Relationship: |
Director |
City: |
Tarrytown |
State: |
NY |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
2 |
|
Direct
Shares |
251,572 |
|
Indirect Shares
|
4,133 |
|
|
Direct
Value |
$25,789,856 |
|
|
Indirect Value
|
$4,145,192 |
|
|
Total
Shares |
255,705 |
|
|
Total
Value |
$29,935,049 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Regeneron Pharmaceuticals Inc |
REGN |
SVP Clinical Developme... |
2016-05-16 |
25,714 |
2016-05-16 |
4,133 |
Premium* |
|
Vaxxinity, Inc. |
VAXX |
Director |
2022-03-31 |
225,858 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
45 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VAXX |
Vaxxinity, Inc. |
Director |
|
2022-03-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
225,858 |
|
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2012-12-18 |
4 |
OE |
$21.25 |
$1,209,090 |
D/D |
38,248 |
39,446 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2012-12-18 |
4 |
D |
$178.62 |
$3,799,069 |
D/D |
(21,269) |
31,969 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2012-12-19 |
4 |
AS |
$176.79 |
$1,848,536 |
D/D |
(10,356) |
21,613 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2012-12-20 |
4 |
AS |
$170.44 |
$1,130,164 |
D/D |
(6,623) |
14,990 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2013-01-02 |
4 |
OE |
$21.25 |
$637,500 |
D/D |
30,000 |
44,990 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2013-01-02 |
4 |
D |
$177.82 |
$2,918,737 |
D/D |
(16,414) |
28,576 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2013-01-03 |
4 |
AS |
$180.83 |
$2,474,091 |
D/D |
(13,586) |
14,990 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clin Devel & Reg Affairs |
|
2013-01-09 |
4 |
OE |
$16.80 |
$99,980 |
D/D |
5,752 |
20,742 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development |
|
2011-07-25 |
4 |
D |
$56.26 |
$788,934 |
D/D |
(14,023) |
10,977 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development |
|
2011-07-25 |
4 |
OE |
$15.64 |
$391,000 |
D/D |
25,000 |
25,000 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development |
|
2011-07-26 |
4 |
AS |
$54.74 |
$602,491 |
D/D |
(10,977) |
0 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development |
|
2011-08-01 |
4 |
OE |
$15.64 |
$236,852 |
D/D |
15,144 |
15,144 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-02-21 |
4 |
D |
$100.32 |
$6,080,596 |
D/D |
(60,612) |
64,398 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-02-21 |
4 |
OE |
$15.64 |
$1,989,055 |
D/D |
109,866 |
72,662 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-02-22 |
4 |
AS |
$94.71 |
$4,745,316 |
D/D |
(49,254) |
15,144 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-07-25 |
4 |
D |
$126.76 |
$1,011,672 |
D/D |
(7,981) |
22,163 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-07-25 |
4 |
OE |
$16.80 |
$252,000 |
D/D |
15,000 |
30,144 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-07-26 |
4 |
AS |
$130.40 |
$916,953 |
D/D |
(7,019) |
15,144 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-08-01 |
4 |
OE |
$15.64 |
$263,093 |
D/D |
14,990 |
30,134 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-09-18 |
4 |
D |
$148.78 |
$1,163,906 |
D/D |
(7,823) |
37,311 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-09-18 |
4 |
OE |
$16.80 |
$252,000 |
D/D |
15,000 |
45,134 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-09-19 |
4 |
AS |
$146.89 |
$1,056,204 |
D/D |
(7,177) |
30,134 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2012-11-08 |
4 |
S |
$138.59 |
$2,099,221 |
D/D |
(15,144) |
14,990 |
0 |
- |
|
REGN |
Regeneron Pharmaceuticals... |
SVP Clinical Development & Reg |
|
2013-12-16 |
4 |
D |
$272.73 |
$5,895,604 |
D/D |
(21,617) |
29,750 |
0 |
- |
|
45 Records found
|
|
Page 1 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|